Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
22 07 2022
Historique:
received: 31 01 2022
accepted: 22 07 2022
pubmed: 23 7 2022
medline: 24 8 2022
entrez: 22 7 2022
Statut: epublish

Résumé

Invasive bacterial disease is a major cause of morbidity and mortality in African children. Despite being caused by diverse pathogens, children with sepsis are clinically indistinguishable from one another. In spite of this, most genetic susceptibility loci for invasive infection that have been discovered to date are pathogen specific and are not therefore suggestive of a shared genetic architecture of bacterial sepsis. Here, we utilise probabilistic diagnostic models to identify children with a high probability of invasive bacterial disease among critically unwell Kenyan children with Bacterial infections are a major cause of severe illness and death in African children. Understanding which children are at risk of life-threatening infection and why, is key to designing new tools to help protect them. Some risk is likely inherited, but scientists do not know which genes are responsible. Genome-wide association studies (GWAS) may be one way to identify bacterial infection risk genes. GWAS look for genetic differences associated with a particular disease. But previous GWAS studies have failed to find genes linked with bacterial infections in African children because they were too small. Malaria is another frequent cause of life-threatening illness in African children. It can be hard for clinicians to determine if a child's illness is caused by malaria, a bacterial infection, or both. Many children in Africa have malaria parasites in their blood, but they do not always cause disease. Most children with suspected severe malaria are treated with antibiotics in case of bacterial infection. Clinicians may then conduct further testing to determine the illness’s actual cause. Scientists may be able to use this data on children with suspected malaria to study bacterial infections. Gilchrist et al. show that children with an unusual alteration in the BIRC6 gene are at increased risk of bacterial infections. In the experiments, Gilchrist et al. used computer modeling to identify a subset of children with likely bacterial infections among 2,200 children admitted to a hospital in Kenya with a high fever and malaria parasites. By combining information on this subset of children with data on children with confirmed bacterial infections and healthy children, Gilchrist created a sample of 5,400 children for a GWAS. The analyses found that children with a variation in the BIRC6 gene on chromosome 2 had a higher risk of bacterial infections. This genetic change is linked with the production of a modified form of BIRC6 in infection-fighting immune cells called monocytes. More studies will help scientists understand how this change might contribute to severe bacterial infections. Learning more may help scientists develop new treatment strategies and identify children most at risk.

Autres résumés

Type: plain-language-summary (eng)
Bacterial infections are a major cause of severe illness and death in African children. Understanding which children are at risk of life-threatening infection and why, is key to designing new tools to help protect them. Some risk is likely inherited, but scientists do not know which genes are responsible. Genome-wide association studies (GWAS) may be one way to identify bacterial infection risk genes. GWAS look for genetic differences associated with a particular disease. But previous GWAS studies have failed to find genes linked with bacterial infections in African children because they were too small. Malaria is another frequent cause of life-threatening illness in African children. It can be hard for clinicians to determine if a child's illness is caused by malaria, a bacterial infection, or both. Many children in Africa have malaria parasites in their blood, but they do not always cause disease. Most children with suspected severe malaria are treated with antibiotics in case of bacterial infection. Clinicians may then conduct further testing to determine the illness’s actual cause. Scientists may be able to use this data on children with suspected malaria to study bacterial infections. Gilchrist et al. show that children with an unusual alteration in the BIRC6 gene are at increased risk of bacterial infections. In the experiments, Gilchrist et al. used computer modeling to identify a subset of children with likely bacterial infections among 2,200 children admitted to a hospital in Kenya with a high fever and malaria parasites. By combining information on this subset of children with data on children with confirmed bacterial infections and healthy children, Gilchrist created a sample of 5,400 children for a GWAS. The analyses found that children with a variation in the BIRC6 gene on chromosome 2 had a higher risk of bacterial infections. This genetic change is linked with the production of a modified form of BIRC6 in infection-fighting immune cells called monocytes. More studies will help scientists understand how this change might contribute to severe bacterial infections. Learning more may help scientists develop new treatment strategies and identify children most at risk.

Identifiants

pubmed: 35866869
doi: 10.7554/eLife.77461
pii: 77461
pmc: PMC9391038
doi:
pii:

Substances chimiques

BIRC6 protein, human 0
Inhibitor of Apoptosis Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
ID : 209265/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202800/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202800
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203141/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 223253/Z/21/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : HCUZZ0
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098532
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 085475/B/08/Z
Pays : United Kingdom
Organisme : European Research Council
ID : 294557
Pays : International

Informations de copyright

© 2022, Gilchrist et al.

Déclaration de conflit d'intérêts

JG, SK, JW, GB, SU, CN, NM, SM, SM, MM, KA, KR, AM, DK, AH, KM, JS, TW No competing interests declared

Références

G3 (Bethesda). 2011 Nov;1(6):457-70
pubmed: 22384356
Sci Transl Med. 2022 Jul 20;14(654):eabn5040
pubmed: 35857826
PLoS Biol. 2006 Mar;4(3):e72
pubmed: 16494531
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Nat Rev Immunol. 2013 Oct;13(10):722-37
pubmed: 24064518
Shock. 2002 Dec;18(6):487-94
pubmed: 12462554
J Innate Immun. 2010;2(5):461-8
pubmed: 20571256
Lancet Haematol. 2018 Aug;5(8):e333-e345
pubmed: 30033078
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Lancet. 2011 Oct 8;378(9799):1316-23
pubmed: 21903251
PLoS Med. 2012;9(8):e1001297
pubmed: 22927801
Nat Cell Biol. 2004 Sep;6(9):849-60
pubmed: 15300255
Elife. 2022 Jul 22;11:
pubmed: 35866869
JAMA. 2006 Aug 9;296(6):671-8
pubmed: 16896110
J Immunol. 2001 Jun 1;166(11):6952-63
pubmed: 11359857
Cell. 2016 Oct 20;167(3):643-656.e17
pubmed: 27768888
J Cell Biol. 1998 Jun 15;141(6):1415-22
pubmed: 9628897
Nat Commun. 2019 May 15;10(1):2176
pubmed: 31092817
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Semin Immunol. 2014 Dec;26(6):454-70
pubmed: 25453225
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
J Immunol. 2002 Mar 1;168(5):2493-500
pubmed: 11859143
PLoS Genet. 2014 May 15;10(5):e1004383
pubmed: 24830394
Immunol Res. 1993;12(3):295-311
pubmed: 8288947
Nat Genet. 2021 Sep;53(9):1290-1299
pubmed: 34493866
Am J Hum Genet. 2016 Jun 2;98(6):1092-1100
pubmed: 27236921
Mol Cell. 2004 Jun 18;14(6):801-11
pubmed: 15200957
Genet Epidemiol. 2009 Jan;33(1):79-86
pubmed: 18642345
Am J Hum Genet. 2011 Jan 7;88(1):76-82
pubmed: 21167468
Ann Surg. 2013 Feb;257(2):352-63
pubmed: 22968077
PLoS One. 2010 Jan 25;5(1):e8091
pubmed: 20111602
N Engl J Med. 2005 Jan 6;352(1):39-47
pubmed: 15635111
Nat Commun. 2019 Dec 16;10(1):5732
pubmed: 31844061
Nat Genet. 2010 Sep;42(9):772-6
pubmed: 20694013
Arthritis Res Ther. 2011 Feb 01;13(1):101
pubmed: 21345260
Elife. 2021 Jul 06;10:
pubmed: 34225842
Immunol Res. 2007;38(1-3):347-52
pubmed: 17917042
Cell. 2019 Oct 31;179(4):984-1002.e36
pubmed: 31675503
Bioinformatics. 2012 Jan 1;28(1):134-5
pubmed: 22057162
Lancet. 2009 Oct 17;374(9698):1364-70
pubmed: 19747721
Nat Rev Immunol. 2004 Mar;4(3):223-31
pubmed: 15039759
Genome Res. 2012 Oct;22(10):2008-17
pubmed: 22722343
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
Clin Infect Dis. 2017 Jun 15;64(suppl_3):S368-S377
pubmed: 28575366
Elife. 2019 Nov 06;8:
pubmed: 31692446
Nature. 2015 Oct 8;526(7572):253-7
pubmed: 26416757
Bioinformatics. 2016 May 15;32(10):1479-85
pubmed: 26708335
Nat Genet. 2007 Jul;39(7):906-13
pubmed: 17572673
Nat Microbiol. 2021 Oct;6(10):1289-1299
pubmed: 34580442
Nat Rev Immunol. 2006 Nov;6(11):813-22
pubmed: 17039247
Genome Biol. 2001;2(7):REVIEWS3009
pubmed: 11516343
Nat Methods. 2011 Dec 04;9(2):179-81
pubmed: 22138821
BMC Med. 2014 Feb 19;12:31
pubmed: 24548672
Lancet Glob Health. 2019 Mar;7(3):e337-e346
pubmed: 30784634
Malar J. 2019 Nov 6;18(1):355
pubmed: 31694718
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Nat Commun. 2018 Feb 9;9(1):599
pubmed: 29426817
PLoS Med. 2007 Aug;4(8):e251
pubmed: 17713980
Nat Commun. 2018 Mar 9;9(1):1014
pubmed: 29523850

Auteurs

James J Gilchrist (JJ)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Silvia N Kariuki (SN)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

James A Watson (JA)

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Gavin Band (G)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Sophie Uyoga (S)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Carolyne M Ndila (CM)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Neema Mturi (N)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Salim Mwarumba (S)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Shebe Mohammed (S)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Moses Mosobo (M)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Kaur Alasoo (K)

Institute of Computer Science, University of Tartu, Tartu, Estonia.

Kirk A Rockett (KA)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Alexander J Mentzer (AJ)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Dominic P Kwiatkowski (DP)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Wellcome Sanger Institute, Cambridge, United Kingdom.

Adrian V S Hill (AVS)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
The Jenner Institute, University of Oxford, Oxford, United Kingdom.

Kathryn Maitland (K)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Division of Medicine, Imperial College, London, United Kingdom.

J Anthony G Scott (JAG)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.

Thomas N Williams (TN)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Institute for Global Health Innovation, Department of Surgery and Cancer, Imperial College, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH